A new independent
518 page research with title 'Obesity - Pipeline Review, H2 2017’guarantees you
will remain better informed than your competition. The study covers
geographic analysis that includes regions and important players/vendors such as
Abeome Corp, Akron Molecules AG, Amgen Inc, Athersys Inc, Biophytis SAS, etc.
Obesity is defined as having an excessive amount of body fat.
Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.
Request a sample report @ https://www.htfmarketreport.com/sample-report/806316-obesity-pipeline-review-1
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 16, 28, 125 and 27 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 57 and 13 molecules, respectively.
Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/806316-obesity-pipeline-review-1
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Place a Purchase Order for Obesity - Pipeline Review Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=806316
Companies mentioned in the Report
Abeome Corp
Adamas Pharmaceuticals Inc
Aegis Therapeutics LLC
Akron Molecules AG
Amgen Inc
Antag Therapeutics ApS
Aoxing Pharmaceutical Company Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Athersys Inc
Biophytis SAS
BioRestorative Therapies Inc
Biozeus
Boehringer Ingelheim GmbH
Braasch Biotech LLC
C3J Therapeutics Inc
Callitas Therapeutics Inc
Carmot Therapeutics Inc
Cereno Scientific AB
Chong Kun Dang Pharmaceutical Corp
CohBar Inc
CoMentis Inc
Connexios Life Sciences Pvt Ltd
ConSynance Therapeutics Inc
Corcept Therapeutics Inc
Daiichi Sankyo Co Ltd
DiscoveryBiomed Inc
Eisai Co Ltd
Eli Lilly and Co
Eternygen GmbH
Evotec AG
FibroGen Inc
Genmedica Therapeutics SL
Gila Therapeutics Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Glucox Biotech AB
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hyundai Pharmaceutical Co Ltd
Immungenetics AG
Intarcia Therapeutics Inc
Ionis Pharmaceuticals Inc
Ixchel Pharma LLC
Johnson & Johnson
Juno Therapeutics Inc
Kissei Pharmaceutical Co Ltd
Laboratorios Silanes SA de CV
Lead Discovery Center GmbH
Leading BioSciences Inc
Lotus Pharmaceutical Co Ltd
Magnus Life Ltd
MedImmune LLC
Merck & Co Inc
Naia Ltd
NeuroNano Pharma Inc
NGM Biopharmaceuticals Inc
NIBEC
Nordic Bioscience A/S
Novartis AG
Novo Nordisk AS
ObeTherapy Biotechnology
Omeros Corp
OPKO Biologics Ltd
OPKO Health Inc
Oramed Pharmaceuticals Inc
Orexigen Therapeutics Inc
Palatin Technologies Inc
Pfizer Inc
PharmaIN Corp
Poxel SA
Prometheon Pharma LLC
ReCyte Therapeutics Inc
Renova Therapeutics Inc
Reviva Pharmaceuticals Inc
Saniona AB
Sanofi
Seres Therapeutics Inc
Shionogi & Co Ltd
Sinil Pharmaceutical Co Ltd
Sorrento Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Toray Industries Inc
Vicore Pharma AB
Viking Therapeutics Inc
Vivus Inc
WhanIn Pharmaceutical Co Ltd
XL-protein GmbH
Yuyu Pharma Inc
Zafgen Inc
Zealand Pharma AS
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/806316-obesity-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
sales@htfmarketreport.com
Ph: +1 (206) 317 1218
Obesity is defined as having an excessive amount of body fat.
Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.
Request a sample report @ https://www.htfmarketreport.com/sample-report/806316-obesity-pipeline-review-1
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 16, 28, 125 and 27 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 57 and 13 molecules, respectively.
Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/806316-obesity-pipeline-review-1
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Place a Purchase Order for Obesity - Pipeline Review Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=806316
Companies mentioned in the Report
Abeome Corp
Adamas Pharmaceuticals Inc
Aegis Therapeutics LLC
Akron Molecules AG
Amgen Inc
Antag Therapeutics ApS
Aoxing Pharmaceutical Company Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Athersys Inc
Biophytis SAS
BioRestorative Therapies Inc
Biozeus
Boehringer Ingelheim GmbH
Braasch Biotech LLC
C3J Therapeutics Inc
Callitas Therapeutics Inc
Carmot Therapeutics Inc
Cereno Scientific AB
Chong Kun Dang Pharmaceutical Corp
CohBar Inc
CoMentis Inc
Connexios Life Sciences Pvt Ltd
ConSynance Therapeutics Inc
Corcept Therapeutics Inc
Daiichi Sankyo Co Ltd
DiscoveryBiomed Inc
Eisai Co Ltd
Eli Lilly and Co
Eternygen GmbH
Evotec AG
FibroGen Inc
Genmedica Therapeutics SL
Gila Therapeutics Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Glucox Biotech AB
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hyundai Pharmaceutical Co Ltd
Immungenetics AG
Intarcia Therapeutics Inc
Ionis Pharmaceuticals Inc
Ixchel Pharma LLC
Johnson & Johnson
Juno Therapeutics Inc
Kissei Pharmaceutical Co Ltd
Laboratorios Silanes SA de CV
Lead Discovery Center GmbH
Leading BioSciences Inc
Lotus Pharmaceutical Co Ltd
Magnus Life Ltd
MedImmune LLC
Merck & Co Inc
Naia Ltd
NeuroNano Pharma Inc
NGM Biopharmaceuticals Inc
NIBEC
Nordic Bioscience A/S
Novartis AG
Novo Nordisk AS
ObeTherapy Biotechnology
Omeros Corp
OPKO Biologics Ltd
OPKO Health Inc
Oramed Pharmaceuticals Inc
Orexigen Therapeutics Inc
Palatin Technologies Inc
Pfizer Inc
PharmaIN Corp
Poxel SA
Prometheon Pharma LLC
ReCyte Therapeutics Inc
Renova Therapeutics Inc
Reviva Pharmaceuticals Inc
Saniona AB
Sanofi
Seres Therapeutics Inc
Shionogi & Co Ltd
Sinil Pharmaceutical Co Ltd
Sorrento Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Toray Industries Inc
Vicore Pharma AB
Viking Therapeutics Inc
Vivus Inc
WhanIn Pharmaceutical Co Ltd
XL-protein GmbH
Yuyu Pharma Inc
Zafgen Inc
Zealand Pharma AS
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/806316-obesity-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
sales@htfmarketreport.com
Ph: +1 (206) 317 1218
No comments:
Post a Comment